Roivant Sciences shares drop as lupus treatment misses trial goal
Roivant Sciences Ltd. shares (ROIV) fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to meet its main goal in a trial involving patients with moderate to severe lupus. Due to the high placebo response rate seen in the trial, "it was not possible to truly assess the impact of the drug, or to establish sufficient differentiation from other therapies in lupus patients," Roivant CEO Matt Gline said in a statement. Roivant will not pursue further development of brepocitinib in systemic lupus erythematosus, the most common type of lupus, Gline sad, but is still enthusiastic about the treatment's potential in an eye condition called non-infectious uveitis and dermatomyositis, an inflammatory disease that causes muscle weakness and skin rash. Roivant shares have gained 14.3% in the year to date, while the S&P 500 is up 18.8%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-27-23 0853ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy